Core Viewpoint - A securities fraud class action lawsuit has been filed against Sarepta Therapeutics, Inc. for alleged misrepresentations regarding the safety risks of its product ELEVIDYS, which is intended for treating Duchenne muscular dystrophy [3][4]. Group 1: Lawsuit Details - The lawsuit was initiated in the United States District Court for the Southern District of New York on behalf of investors who purchased Sarepta securities between June 22, 2023, and June 24, 2025 [3]. - The allegations include violations of the Securities Exchange Act of 1934 against Sarepta and certain senior officers [3]. Group 2: Legal Participation - Investors wishing to serve as lead plaintiffs must file necessary documents by August 25, 2025, with the option to remain as absent class members if they choose not to take action [5]. - All legal representation is on a contingency fee basis, meaning shareholders incur no fees or expenses [5]. Group 3: Law Firm Background - Bernstein Liebhard LLP has recovered over $3.5 billion for clients since 1993 and has represented both individual investors and large pension funds [6]. - The firm has been recognized multiple times for its success in litigating class actions, being named to The National Law Journal's "Plaintiffs' Hot List" thirteen times and listed in The Legal 500 for sixteen consecutive years [6].

SAN DIEGO, July 07, 2025 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, PLLP, is investigating whether BellRing Brands, Inc. (NYSE: BRBR), or any of its executive officers, violated securities laws by misrepresenting or failing to timely disclose material information to investors. What if I purchased BRBR securities? If you purchased securities and suffered losses on your investment, join our investigation now: [Click Here to Join the Investigation] Or for more information, contact Jim Bake ...

Core Viewpoint - Edelson Lechtzin LLP is investigating securities fraud claims against Hims & Hers Health, Inc. related to its partnership with Novo Nordisk, which may have misled investors regarding the nature of the collaboration and its implications for the company's stock value [1][4]. Company Overview - Hims & Hers Health, Inc. is a telehealth and online pharmacy company that provides prescription and over-the-counter medications, mental health services, and personal care products through a direct-to-consumer platform in the U.S. and the U.K. [3]. Securities Fraud Claims - The complaint alleges that Hims & Hers made materially false and misleading statements and failed to disclose critical facts about its partnership with Novo Nordisk during the class period from April 29, 2025, to June 23, 2025 [4]. - Specifically, Hims & Hers allegedly engaged in deceptive promotion and sale of Novo Nordisk's Wegovy® weight loss drug, creating a substantial risk of termination of the partnership [4]. Partnership Details - On April 29, 2025, Hims & Hers announced a long-term collaboration with Novo Nordisk, which included the immediate sale of a bundled offering of Wegovy® on its platform [5]. - However, on June 23, 2025, Novo Nordisk terminated the partnership, citing Hims & Hers' failure to comply with legal standards regarding the sale of compounded drugs and deceptive marketing practices that jeopardized patient safety [5]. Stock Impact - Following the termination announcement by Novo Nordisk, Hims & Hers' stock price dropped by $22.24 per share, representing a decline of 34.63%, closing at $41.98 per share on June 23, 2025 [5].

Core Insights - Iovance Biotherapeutics Inc. is undergoing a leadership transition with the resignation of CFO Jean-Marc Bellemin, effective July 10, 2025, amid commercial challenges and a class-action lawsuit [1][2][3] Group 1: Leadership Changes - CFO Jean-Marc Bellemin's resignation is effective July 10, 2025, and he is leaving to pursue other endeavors [1][2] - Bellemin's departure aligns with the terms of his executive employment agreement, and a successor has not yet been named [2] Group 2: Commercial Performance - Iovance's flagship drug, Amtagvi, has faced significant commercial setbacks, with first-quarter sales underperforming Wall Street expectations [3] - The company has revised its full-year revenue projections downward, leading to a downgrade from UBS [3] Group 3: Legal Challenges - Iovance is defending against a class-action securities fraud lawsuit related to its portrayal of authorized treatment centers (ATCs) crucial for Amtagvi's administration [4][5] - The lawsuit alleges discrepancies between the company's claims about ATC operations and the actual performance, including delays in patient treatment initiation and high patient drop-off rates [5][6] Group 4: Market Reaction - Following the disclosure of disappointing first-quarter results and revised revenue guidance, Iovance's stock fell over 44%, from $3.17 per share to $1.75 per share within a day [6][7] - The market's swift reaction reflects investor concerns regarding the company's commercial execution and the accuracy of its operational updates [7]

Core Viewpoint - The Compass Diversified class action lawsuit alleges violations of the Securities Exchange Act of 1934 by the company and its executives, primarily related to misleading financial statements and irregularities in its subsidiary, Lugano Holdings [1][4][5]. Group 1: Lawsuit Details - The lawsuit is titled Augenbaum v. Compass Diversified Holdings, No. 25-cv-01003 (C.D. Cal.) and seeks to represent purchasers of Compass Diversified Holdings publicly traded securities [1]. - The class action lawsuit claims that Compass Diversified made false statements and failed to disclose significant financial irregularities related to Lugano Holdings, which affected the reported financial results for fiscal 2024 [4][5]. - The lawsuit was initiated after Compass Diversified announced the need to restate its 2024 financial statements due to identified irregularities in Lugano's accounting practices, leading to a stock price drop of over 62% [5]. Group 2: Financial Impact - The acquisition of Lugano Holdings was announced on September 7, 2021, with an enterprise value of $256 million [3]. - Following the announcement of the need for financial restatement, Compass Diversified's stock experienced a significant decline, indicating a loss of investor confidence [5]. Group 3: Legal Representation - The plaintiffs are represented by Robbins Geller Rudman & Dowd LLP, a law firm with extensive experience in prosecuting investor class actions, particularly those involving financial fraud [6][8]. - The firm has a strong track record, having recovered over $2.5 billion for investors in securities-related class action cases in 2024 alone [8].

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Harrow, Inc. and its officers or directors [1] Financial Performance - On May 8, 2025, Harrow reported first-quarter 2025 revenue of $47.8 million, which missed consensus estimates of $57.0 million [3] - The company also reported an adjusted EBITDA of -$1.9 million, falling short of the expected $11.9 million [3] - Following the financial results announcement, Harrow's stock price decreased by $1.00 per share, or 4.07%, closing at $23.59 per share on the same day [3]

Core Insights - Pomerantz LLP is investigating claims on behalf of investors of BellRing Brands, Inc. regarding potential securities fraud or unlawful business practices by the company and its officers or directors [1] - During the second quarter 2025 earnings call, BellRing disclosed that certain customers are optimizing their inventories, leading to a slowdown in sales growth projected for the third quarter to low-single-digits [3] - Following the earnings call, BellRing's stock price dropped by $14.88 per share, or 18.97%, closing at $63.55 on May 6, 2025 [3] Company Overview - BellRing Brands, Inc. is publicly traded on the NYSE under the ticker BRBR [1] - The company is facing scrutiny due to claims of potential securities fraud, which may impact investor confidence and stock performance [1] Legal Context - Pomerantz LLP is recognized for its expertise in corporate, securities, and antitrust class litigation, having a long history of fighting for victims of securities fraud and corporate misconduct [4] - The firm has successfully recovered multimillion-dollar damages on behalf of class members in the past, indicating a strong track record in handling such cases [4]

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Gilead Sciences, Inc. and its officers or directors [1] Company Developments - On June 10, 2025, Gilead announced that the U.S. FDA placed a clinical hold on its HIV treatment trials for GS-1720 and GS-4182 due to safety concerns related to decreases in CD4+ T-cell and absolute lymphocyte counts in trial participants [3] - Following the announcement of the clinical hold, Gilead's stock price decreased by $2.91, or 2.58%, closing at $110.09 per share on the same day [3] Legal Context - Pomerantz LLP is recognized for its expertise in corporate, securities, and antitrust class litigation, having a long history of fighting for victims of securities fraud and corporate misconduct [4]

Group 1 - A class action lawsuit has been filed against Reckitt Benckiser Group Plc for alleged securities fraud and unlawful business practices [2][4] - Investors who purchased Reckitt securities during the Class Period have until August 4, 2025, to request appointment as Lead Plaintiff [2] - Reckitt's American Depositary Share (ADS) price experienced significant declines following jury verdicts related to its subsidiary Mead Johnson's negligence in warning about health risks associated with its products [4][5] Group 2 - On March 15, 2024, an Illinois jury awarded $60 million against Reckitt's Mead Johnson subsidiary for failing to warn about the risk of necrotizing enterocolitis (NEC) in preterm infants, leading to a nearly 14% drop in Reckitt's ADS price [4] - A subsequent lawsuit against Abbott Laboratories resulted in a $495 million award, similarly impacting Reckitt's ADS price with a nearly 9% decline [5] - Pomerantz LLP is recognized for its expertise in corporate, securities, and antitrust class litigation, having a long history of fighting for victims of securities fraud [6]

Group 1 - The investigation by Pomerantz LLP concerns potential securities fraud or unlawful business practices by Vera Bradley and its officers or directors [1] - Vera Bradley reported disappointing financial results for Q1 of fiscal year 2026, with CEO Jackie Ardrey acknowledging the need for significant improvements to achieve positive growth [3] - Following the announcement of poor financial results, Vera Bradley's stock price dropped by $0.45, or 19.15%, closing at $1.90 per share on June 11, 2025 [4] Group 2 - Vera Bradley announced key leadership changes, including the departure of CEO Jackie Ardrey at the end of July 2025 [3]